Overview

Gender

male

Robert Hershberg (M.D., Ph.D.) Chief Executive Officer at VentiRX Pharmaceuticals.Dr. Robert Hershberg is a founder of VentiRx Pharmaceuticals and serves as Chief Executive Officer and member of the Board of Directors. VentiRx Pharmaceuticals is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The Company's initial focus is developing novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for oncology and allergy.

Prior to VentiRx, Dr. Hershberg served as Senior Vice President and Chief Medical Officer at Dendreon Corporation, developing immunotherapy approaches for cancer. In this capacity, Dr. Hershberg led the Clinical, Regulatory, and Biometrics groups, focusing on the development of Provenge™ in metastatic prostate cancer.

Prior to joining Dendreon, Dr. Hershberg was the Vice President of Medical Genetics at Corixa Corporation (subsequently acquired by GSK). He led a research group focused on innate immunity and inflammatory disease, with a particular emphasis on Toll-like receptors (TLRs), and was an active member of the clinical development team for various products.

Prior to joining Corixa, Dr. Hershberg was an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women's Hospital in Boston, Massachusetts.He completed his Undergraduate Degree in Molecular Biology and M.D. at UCLA, and his Ph.D. in Biology at the Salk Institute.Dr. Hershberg is clinically-boarded in Medical Genetics, and holds current clinical and research faculty positions at the University of Washington School of Medicine.